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Abstract
Background: Mesenchymal stem cells (MSCs) are capable of immunomodulation and tissue regeneration,
highlighting their potential translational application for treating inflammatory bone disorders. MSC-mediated
immunomodulation is regulated by proinflammatory cytokines and pathogen-associated molecular patterns
such as lipopolysaccharide (LPS). Previous studies showed that MSCs exposed to interferon gamma (IFN-γ)
and the proinflammatory cytokine tumor necrosis factor alpha (TNF-α) synergistically suppressed T-cell activation.
Methods: In the current study, we developed a novel preconditioning strategy for MSCs using LPS plus TNF-α
to optimize the immunomodulating ability of MSCs on macrophage polarization.
Results: Preconditioned MSCs enhanced anti-inflammatory M2 macrophage marker expression (Arginase 1 and
CD206) and decreased inflammatory M1 macrophage marker (TNF-α/IL-1Ra) expression using an in-vitro coculture
model. Immunomodulation of MSCs on macrophages was significantly increased compared to the combination of
IFN-γ plus TNF-α or single treatment controls. Increased osteogenic differentiation including alkaline phosphate
activity and matrix mineralization was only observed in the LPS plus TNF-α preconditioned MSCs. Mechanistic
studies showed that increased prostaglandin E2 (PGE2) production was associated with enhanced Arginase 1
expression. Selective cyclooxygenase-2 inhibition by Celecoxib decreased PGE2 production and Arginase 1
expression in cocultured macrophages.
Conclusions: The novel preconditioned MSCs have increased immunomodulation and bone regeneration potential
and could be applied to the treatment of inflammatory bone disorders including periprosthetic osteolysis, fracture
healing/nonunions, and osteonecrosis.
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Background
Mesenchymal stem cells (MSCs) have been specifically
defined by the International Society for Cellular Therapy
[1]. Potential translational applications of MSCs are
highlighted by their properties for immunomodulation
and tissue regeneration including those that relate to
bone. MSC-based cell therapies have been applied to
clinical trials of inflammatory disorders including graft-
versus-host disease, diabetes, myocardial infarction, and
osteoarthritis [2].
MSC-based therapies may have great potential for
treatment of inflammatory bone disorders. Inflammation
has a crucial but distinct role in bone healing and the re-
modeling process [3]. For example, acute inflammation
is necessary for successful fracture healing and bone re-
generation [4]. Depletion of macrophages greatly im-
paired bone healing in a murine bone injury model [5].
However, unresolved inflammation with excessive proin-
flammatory cytokines and chemokines mainly secreted
by macrophages leads to impaired bone formation and
increased bone destruction (osteolysis) [6]. In addition,
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sequential exposure of MSC-lineage cells to inflamma-
tory M1 macrophages (tumor necrosis factor alpha
(TNF-α)/interleukin-1 receptor antagonist (IL-1Ra)high)
and anti-inflammatory M2 macrophages (Arginase 1
(Arg1)high and CD206high) further enhanced osteogenic
differentiation in vitro [7]. Therefore, stimulation of
MSCs by inflammatory signals and sequential modula-
tion of macrophage polarization status is crucial for op-
timizing bone formation. Studies using transgenic
animals demonstrated that NF-κB signaling (a major
downstream signaling of inflammatory stimulation)
negatively regulated bone formation [8]; however, the ef-
fects of inflammatory ligand stimulation on osteogenic
differentiation of MSCs depended on the dose, type, and
timing of the stimulation [9]. Exposure of MSCs to a
lower dose (0.1–5 ng/ml) of TNF-α inhibited, while a
higher dose (50 ng/ml) increased, osteogenic differenti-
ation in vitro [10, 11]. The induction of osteogenesis me-
diated by inflammatory stimulation, including TNF-α
and lipopolysaccharide (LPS), was only observed with
early treatment of MSCs [12–16].
Previous studies have shown that in addition to osteo-
genic potential, MSC-mediated immunomodulation could
be regulated by proinflammatory cytokines [17, 18] or bac-
terial endotoxin [19]. MSCs exposed to LPS attenuated the
response to sepsis by upregulating IL-10 secretion in mac-
rophages by secretion of prostaglandin E2 (PGE2) [19].
MSCs exposed to the combination of interferon gamma
(IFN-γ) and proinflammatory cytokines such as TNF-α,
but not by either IFN-γ or TNF-α alone, reduced T-
lymphocyte-mediated and macrophage-mediated immune
responses [17, 18]. These results suggest that stimulation
by multiple inflammatory factors is required to enhance
MSC-mediated immunomodulation in a synergistic man-
ner. However, the application of IFN-γ plus TNF-α pre-
conditioned MSCs in bone disorders could be limited by
the potential detrimental effect of IFN-γ plus TNF-α on
MSC self-renewal and lineage differentiation [20].
In the current study, we show that preconditioning of
MSCs with TNF-α and LPS enhances the immunomodu-
latory properties of MSCs on M1 to M2 macrophage
polarization and simultaneously increases the osteogenic
differentiation of MSCs. The strategic use of precondi-
tioned MSCs could be applied to inflammatory bone dis-
orders and bone tissue engineering, as well as chronic
inflammatory disorders with excessive macrophage-
mediated proinflammatory activation.
Methods
Isolation of murine mesenchymal stem cells and
macrophages
The methods of isolating murine bone marrow-derived
MSCs and macrophages have been described previously
[21, 22]. Stanford’s Administrative Panel on Laboratory
Animal Care (APLAC) approved this isolation protocol
(APLAC 17566). In brief, bone marrow was collected from
the femurs and tibias of C57BL/6 J male mice 8–10 weeks
old. Institutional guidelines for the care and use of labora-
tory animals were observed in all aspects of this project.
For MSC isolation, the cells were carefully suspended and
passed through a 70-μm strainer, spun down, and resus-
pended in α-MEM supplied with 10% MSC certified fetal
bovine serum (FBS; Invitrogen) and antibiotic antimycotic
solution (100 units of penicillin, 100 μg of streptomycin,
and 0.25 μg of Amphotericin B per ml; Hyclone, Thermo
Scientific). The fresh medium was replaced on the next
day to remove the unattached cells (passage 1). The
immunophenotype of isolated MSCs (Sca1+/CD105
+/CD44+/CD45–/CD34–/CD11b–; Additional file 1: Figure
S1) was characterized by LSR II flow cytometer (BD Bio-
science) at passage 4. For macrophage isolation, the bone
marrow cells were washed three times with culture
medium (RPMI 1640 medium supplemented with 10%
heat-inactivated FBS, and the antibiotic/antimycotic solu-
tion), resuspended in the culture medium containing 30%
of L929 cells conditioned medium and 10 ng/ml mouse
macrophage colony stimulation factor (M-CSF), and
replated in T-175 culture flasks at a concentration of
4 × 107 cells per flask. Cells were allowed to expand for
5–7 days, with a medium change on the second day to
remove nonadherent cells. Macrophages were con-
firmed by double-positive staining of cells (> 98.5%)
using the surface markers F4/80 and CD11b for flow
cytometric analysis after day 7.
Preconditioning of mesenchymal stem cells and coculture
with macrophages
A summary of the experimental strategy is illustrated in
Fig. 1a. At day 0, MSCs (1 × 104 cells) were seeded in 24-
well transwell plates (0.3 μm; Corning) in the bottom
chamber with MSC growth medium. After cell attachment
(day 1), the cells were treated with 20 ng/ml TNF-α and
1–20 μg/ml LPS for 3 days as indicated in the figure le-
gend. The cells treated with 20 ng/ml TNF-α or 20 μg/ml
LPS alone or the combination of 20 ng/ml IFN-γ and
20 ng/ml TNF-α [17] were used as controls. The dose of
TNF-α and IFN-γ was determined according to previous
studies of immunomodulation by MSCs [17, 18]. The dose
of LPS was titrated (Additional file 1: Figure S1) in the
range of previous studies on LPS-treated MSCs [10, 11].
Primary macrophages (2 × 103 cells) were seeded to the in-
sert of a separate transwell plate and polarized into the
M1 phenotype by exposure to 20 ng/ml IFN-γ (day 3) for
24 hours. At day 4, MSCs and macrophages were washed
three times with PBS and the inserts with the M1 macro-
phages were moved to the plates containing the precondi-
tioned MSCs at the bottom of the well. This coculture
was carried out in MSC growth medium for 24 hours.
Lin et al. Stem Cell Research & Therapy  (2017) 8:277 Page 2 of 9
Celecoxib (25 μM) was used to block the cyclooxygen-
ase (COX) signaling in selected groups for further
mechanistic experiments. The medium was supple-
mented with 30 μg/ml polymyxin B1 to inactivate any
trace amounts of LPS which could potentially impact
the culture system.
Quantitative PCR
Cellular RNA from macrophages in the coculture system
was extracted using the RNeasy RNA purification kit
(Qiagen, Valencia, CA, USA). RNA was reverse tran-
scribed into complementary DNA (cDNA) using a high-
capacity cDNA archive kit (Applied Biosystems, Foster
City, CA, USA). Probes for 18 s rRNA, TNF-α, IL-1Ra,
Arg1, and CD206 were purchased from Applied Biosys-
tems. Reverse-transcriptase polymerase chain reaction
(RT-PCR) was performed in an ABI 7900HT Sequencing
Detection System (Applied Biosystems), using 18 s rRNA
as the internal control. The –ΔΔCt relative quantization
method was used to evaluate the gene expression level.
Flow cytometry analysis of macrophage polarization
markers
MSCs were seeded in 10-cm cell culture dishes and pre-
conditioned or left untreated as described earlier. The
conditioned media were collected 24 hours after the
cells were washed and replaced with fresh medium. The
conditioned media were diluted with macrophage
a
b
c
d
Fig. 1 Immunomodulation of preconditioned MSCs on murine macrophages. a Preconditioning and coculture model. Murine MSCs were
preconditioned with IFN-γ plus TNF-α (I + T, 20 ng/ml each), LPS (20 μg/ml) plus TNF-α (L + T), LPS alone (L), or TNF-α alone (T) for 3 days, and
cocultured with M1 macrophages for 24 hours. b M2 (Arg1 and CD206) and M1 (TNF-α/IL-1Ra) macrophage marker expression in macrophages
measured by quantitative PCR. Data presented as fold-change compared to macrophages cocultured with unstimulated control MSCs. c, d Expression
of M2 macrophage markers (Arg1 and CD206) at protein level examined by flow cytometry. ***p < 0.005. Arg1 Arginase 1, IFN interferon, IL1Ra
interleukin-1 receptor antagonist, MSC mesenchymal stem cell, TNF tumor necrosis factor
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growth medium at 1:1 ratio and used to treat IFN-γ-
polarized macrophages for 24 hours. The cells were
harvested into single cell suspension and stained with
anti-CD206 antibody conjugated with PE (eBioscience),
and processed by flow cytometry fixation and
permeabilization buffer kit (R&D) for the following
intracellular staining of Arg1 (FITC). Stained macro-
phages were analyzed by LSRII.
Prostaglandin E2 quantification
Cellular supernatant from the coculture system was col-
lected at the indicated time points. Concentration of
PGE2 in the supernatant was measured by the PGE2
parameter assay kit (R&D system). The manufacturer’s
protocol was followed carefully.
Osteogenesis assay
After preconditioning (see Preconditioning of mesenchy-
mal stem cells and coculture with macrophages for de-
tails), the MSCs were switched into osteogenic medium
(α-MEM supplemented with 10% FBS, 100 nM dexa-
methasone, 10 mM β-glycerol phosphate, and 50 μM
ascorbate-2-phosphate) supplemented with 30 μg/ml
polymyxin B1 to inactivate the trace LPS in the system.
Cell lysate at week 2 was used for the alkaline phosphat-
ase (ALP) activity assay (QuantiChrome™ Alkaline phos-
phatase assay kit, Cat. No. DALP-250; Bioassay Systems,
Hayward, CA, USA). Extracellular matrix mineralization
by the murine MSCs was identified using Alizarin Red
stain at week 3. Celecoxib (25 μM) was used to block
the COX2 signaling at indicated time points described in
figure legends. The results were photographed, and the
staining was eluted by 10% cetylpyridinium chloride and
quantified by measuring the absorbance at 562 nm.
Statistical analysis
Nonpaired t tests were performed for data with two
groups, and one-way ANOVA with Tukey’s post-hoc test
was performed for data with three or more groups. The
statistical analysis was conducted using Prism 7 (Graph-
Pad Software, San Diego, CA, USA). Data are reported
as mean ± standard error of the mean. The osteogenesis
assay was performed with four replicates. Quantitative
PCR was performed in triplicate. The experiments have
been repeated twice in three or four replicates independ-
ently. p < 0.05 was chosen as the threshold of statistical
significance.
Results
Preconditioned MSCs modulated macrophages into an
anti-inflammatory phenotype
Murine MSCs were preconditioned and cocultured with
murine bone marrow-derived macrophages as described
in Methods and Fig. 1a. MSCs preconditioned with IFN-
γ plus TNF-α were included as a positive control, be-
cause this conditioning has been demonstrated previ-
ously to enhance the modulation of both innate and
adaptive immune responses [17, 18]. Activation of proin-
flammatory cytokines (TNF-α) also induces the produc-
tion of anti-inflammatory cytokines (IL-1Ra) as a
negative feedback mechanism to avoid overwhelming
inflammation. The status of macrophage polarization
was thus shown in the ratio of TNF-α/IL-1Ra expression
[7, 23]. First, LPS dosage was titrated by treating MSCs
with varying dosages of LPS (0.1–20 μg/ml) together
with 20 ng/ml TNF-α [17, 18]. We found that precondi-
tioning with 20 μg/ml LPS optimally enhanced the abil-
ity of MSCs to induce anti-inflammatory phenotypes in
macrophages (Arg1high, CD206high, TNF-α/IL-1Ralow;
Additional file 1: Figure S2). Preconditioned MSCs with
LPS plus TNF-α synergistically enhanced M2 macro-
phage marker (Arg1high and CD206high) and decreased
M1 macrophage marker (TNF-α/IL-1Ralow) expression
in the cocultured M1 macrophages (Fig. 1b). MSCs pre-
conditioned with LPS (20 μg/ml) or TNF-α (20 ng/ml)
alone, or with the combination of IFN-γ and TNF-α
(20 ng/ml each), induced the anti-inflammatory pheno-
types in M1 macrophages at lower levels. M2 marker ex-
pression in macrophages (Arg1 and CD206) at the
protein level was further confirmed using the condi-
tioned medium from MSCs (Fig. 1c, d). The Arg1high
population was increased from 32.5 to 67.9%, and the
CD206+ population was increased from 47.7 to 55.7%,
respectively. Together, the combination of LPS and
TNF-α preconditioning further enhanced the immuno-
modulation by MSCs compared to other conditions.
Preconditioned MSCs with LPS plus TNF-α enhanced
osteogenic differentiation
The osteogenic ability of MSCs using various precondi-
tioning protocols was then examined. MSCs precondi-
tioned with LPS plus TNF-α significantly enhanced ALP
activity (p < 0.005) and bone mineralization (p < 0.01);
however, MSCs preconditioned with LPS increased bone
mineralization (p < 0.05) but had no significant effect on
ALP activity (Fig. 2a, b). MSCs preconditioned with
TNF-α alone or with IFN-γ plus TNF-α did not affect
the ALP activity and mineralization.
Increased prostaglandin E2 production in preconditioned
MSCs is associated with enhanced Arginase 1 expression
in macrophages
Inflammatory stimulation by TNF-α induces PGE2 pro-
duction through the NF-κB/COX2-dependent pathway
[24]. PGE2 secretion by MSCs is associated with the in-
hibition of inflammatory response [19, 25, 26] and the
induction of osteogenic differentiation [27, 28]. We
found that PGE2 production was significantly increased
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in the preconditioned MSCs including the groups
treated with IFN-γ plus TNF-α, LPS plus TNF-α, and
TNF-α alone, which could be reversed by a selective
COX2 inhibitor (25 μM Celecoxib) (Fig. 3). MSCs pre-
conditioned with LPS did not increase PGE2 production
(p = 0.10). In the coculture model, inhibition of COX2
signaling by Celecoxib clearly suppressed Arg1
expression in macrophages cocultured with precondi-
tioned MSCs (Fig. 4). However, the preconditioned
MSC-mediated changes in CD206 and TNF-α/IL-1Ra
were not affected by inhibition of COX2 signaling.
Blocking the COX2/PGE2 pathway does not interfere with
enhanced osteogenesis in preconditioned MSCs
We further examined the effects of increased PGE2 pro-
duction on the osteogenic differentiation of precondi-
tioned MSCs. Inhibition of the COX2/PGE2 pathway by
Celecoxib during the first week of osteogenesis signifi-
cantly enhanced ALP activity and mineralization in both
the untreated and preconditioned (LPS plus TNF-α)
MSCs (Fig. 5a, b). To further clarify how the COX2/
PGE2 pathway regulated the osteogenic differentiation
of MSCs in vitro, the MSCs were treated with Celecoxib
at week 1, week 2, week 3, or continuously during the
osteogenesis (weeks 1–3). Temporal inhibition of COX2
signaling enhanced bone mineralization in MSCs regard-
less of the treatment time points, while continuous treat-
ment showed no significant effects compared to the
untreated controls (Additional file 1: Figure S3).
Discussion
Immunomodulation and tissue regeneration are funda-
mental mechanisms in MSC-based cellular therapy.
These biological features are closely regulated in re-
sponse to local environmental cues including the oxygen
level, presence of growth factors and inflammatory cyto-
kines, and other factors. Changes in the microenviron-
ment during disease progression could provoke
protective “pre-homeostatic” mechanisms in MSCs and
further enhance their therapeutic efficiency [29–32]. In-
deed, our current findings show that MSCs precondi-
tioned with LPS plus TNF-α, macrophage-associated
inflammatory mediators, synergistically enhanced M2
macrophage polarization and osteogenic differentiation.
Previous studies of MSC preconditioning have mainly
focused on studying the effects of a single inflammatory
mediator on MSCs [19, 29–33]. These approaches have
clarified valuable information regarding the biological
features of MSCs. However, as the complex tissue
microenvironment contains multiple inflammatory fac-
tors, we speculated that it might be possible to further
enhance the beneficial osteogenic and immunomodula-
tory properties of MSCs by exposing the cells to mul-
tiple inflammatory mediators. IFN-γ is mainly produced
by activated Th1 lymphocytes and is a crucial regulator
of both innate and adaptive immune response [34]. Ren
et al. [17] demonstrated that MSC-mediated suppression
of T-lymphocyte activation required the presence of
IFN-γ and one of the proinflammatory cytokines TNF-α,
IL-1α, or IL-1β. LPS is a potent ligand for macrophages
that activates the proinflammatory response including
a b
Fig. 2 Increased osteogenic differentiation of MSCs preconditioned
with LPS plus TNF-α. MSCs were preconditioned with IFN-γ plus TNF-α
(I + T, 20 ng/ml each), LPS (20 μg/ml) plus TNF-α (L + T), LPS alone (L),
or TNF-α alone (T) for 3 days in growth media, and replaced by
osteogenic media for 3 weeks. The osteogenic differentiation ability
was examined by ALP activity at week 2 (a) and bone mineralization
(Alizarin Red staining) at week 3 (b). *p < 0.05, **p < 0.01, ***p < 0.005.
ALP alkaline phosphatase, MSC mesenchymal stem cell
Fig. 3 Induction of PGE2 secretion in preconditioned MSCs through
the COX-2-dependent pathway. MSCs were preconditioned with IFN-γ
plus TNF-α (I + T, 20 ng/ml each), LPS (20 μg/ml) plus TNF-α (L + T), LPS
alone (L), or TNF-α alone (T) for 3 days, and replaced with fresh media
with or without Celecoxib (25 μM) to modulate COX2 signaling. After
24 hours of incubation, the supernatants were collected, and PGE2
production was quantified by ELISA. *p < 0.05, **p < 0.01. COX2
cyclooxygenase-2, MSC mesenchymal stem cell, PGE2 prostaglandin E2
Lin et al. Stem Cell Research & Therapy  (2017) 8:277 Page 5 of 9
TNF-α production via TLR4 signaling. TNF-α is a strong
proinflammatory cytokine, produced in high amounts
during inflammatory and immune reaction by various
cells including M1 macrophages and Th1 cells. Our pre-
conditioning strategy using high-dose LPS and TNF-α
could incite physiological protective mechanisms against
an overt inflammatory reaction and enhance the immu-
nomodulatory properties of MSCs [19]. However, the
proinflammatory stimulation-induced immunomodula-
tion could also manipulate the infiltrated MSCs into
tumor-derived MSCs and enhance tumor progression
[35]. Indeed, as both TLR ligands and macrophage-
derived TNF-α are likely to be present at the site of in-
jury, they might work synergistically to induce the
physiological transition from acute inflammation to
tissue regeneration. Previous studies have shown that
the application of MSCs preconditioned by a single fac-
tor improved tissue repair using in-vivo models [32, 36],
demonstrating that ex-vivo conditioning with factors
such as LPS/TNF-α can stably increase their therapeutic
efficiency. The underlying mechanisms of synergistic ef-
fect by LPS plus TNF-α or other proinflammatory cyto-
kines remain unclear.
Crosstalk between MSCs and macrophages including
paracrine regulation and direct cell contact is crucial
for effective immunomodulation and tissue regener-
ation [7, 19, 33]. Our current transwell coculture and
conditioned medium treatment models demonstrated
that paracrine factors secreted by the preconditioned
MSCs were effective in modulating macrophage
polarization from the inflammatory M1 phenotype to-
ward the anti-inflammatory and tissue-regenerative M2
phenotype. Previous studies have shown that direct
PGE2 treatment of macrophages increased M2 markers
including Arg1, IL-10, and MMP9, and that this effect
was blocked by PGE2 inhibitors [37–39]. In the current
study, inhibition of the COX2/PGE2 pathway blocked
the upregulation of M2-related Arg1 expression in
macrophages, which is correlated with tissue repair.
However, blocking of the COX2/PGE2 pathway had
limited effects on CD206 expression and TNF-α/IL-1Ra
ratio, suggesting that other secreted factors are also in-
volved in immunomodulation. A previous proteomic
analysis has identified 118 TNF-induced paracrine fac-
tors in human adipose-derived MSCs including various
cytokines, chemokines, proteinases, and immune mod-
ulators such as long pentraxin 3 [40]. Analysis of para-
crine factors secreted by the preconditioned MSCs is
required to further clarify the underlying mechanisms
of immunomodulation. Nemeth et al. [19] have shown
that MSCs induced anti-inflammatory cytokine produc-
tion in macrophages in the coculture system of direct
Fig. 4 Immunomodulation ability of preconditioned MSCs mediated by PGE2 secretion. MSC/macrophage cocultured experiments were
performed as described in Fig. 1a. Media were supplied with or without 25 μM Celecoxib to modulate COX2 signaling. M2 (Arg1 and CD206) and
M1 (TNF-α/IL-1Ra) macrophage marker expression in macrophages was measured by quantitative PCR. Data presented as fold-change compared
to macrophages cocultured with unstimulated control MSCs. *p < 0.05, **p < 0.01, ***p < 0.005. Arg1 Arginase 1, IL1Ra interleukin-1 receptor
antagonist, MSC mesenchymal stem cell, TNF tumor necrosis factor
a b
Fig. 5 Inhibition of COX-2/PGE2 pathway increased osteogenesis in
untreated or preconditioned MSCs. MSCs were preconditioned with
LPS plus TNF-α in growth media, and replaced with osteogenic media
for 3 weeks. Media were supplied with or without 25 μM Celecoxib
during the first week of osteogenesis. Osteogenic differentiation ability
examined by ALP activity at week 2 (a) and bone mineralization
(Alizarin Red staining) at week 3 (b). *p < 0.05, **p < 0.01. ALP alkaline
phosphatase, COX2 cyclooxygenase-2, MSC mesenchymal stem cell
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contact or transwell (paracrine regulation only) models.
The induction is higher with direct cell-to-cell contact
compared to paracrine regulation alone, indicating that
both physical contact and paracrine factors are involved
in the MSC-mediated immunomodulation. Our study
focused on the transwell system to clarify the MSC-
mediated paracrine factors including nitric oxide and
PGE2. Currently, the molecular candidates involved in
the immunomodulation via physical contact between
MSCs and macrophages remain unclear. Our data
showed that MSC preconditioning alone increased
osteogenic differentiation in the absence of macro-
phages in vitro. Sequential modulation of macrophage
polarization status by the preconditioned MSCs could
further enhance the osteogenic potential during this
crosstalk [7].
MSCs can modulate adaptive and innate immunity by
distinct mechanisms. Ren et al. [17] showed that MSC-
mediated suppression of T-cell proliferation required
iNOS-dependent nitric oxide production. Exposure of
LPS plus TNF-α synergistically induced iNOS expression
in MSCs (Additional file 1: Figure S4); however, selective
inhibition of iNOS activity showed a limited effect on
M2 macrophage polarization (data not shown). In
addition, mechanistic studies demonstrated that the
IFN-γ and TNF-α-induced immunomodulation in hu-
man MSCs is mediated by indoleamine 2,3-dioxygenase
(IDO) instead of the iNOS pathway [18]. The different
potential mechanisms to modulate macrophage
polarization between human and mouse MSCs exposed
to LPS plus TNF-α remain to be clarified.
The critical roles of COX2 in bone formation and re-
pair have been demonstrated in COX2 knockout trans-
genic mouse [28, 41, 42], and by rat and rabbit models
using nonselective nonsteroidal anti-inflammatory drugs
(NSAIDs) [43–45]. However, clinical findings regarding
the effects of COX-2 inhibitors and other NSAIDs on
bone formation remain controversial [46–48]. Our data
showed that transient inhibition of COX2 in MSCs by
the selective COX-2 inhibitor Celecoxib increased
osteogenesis, regardless of the treatment time points
(Additional file 1: Figure S3). Interestingly, continuous
treatment with Celecoxib had no significant effects on
osteogenic differentiation. Other in-vitro studies showed
that the suppressive effect of Celecoxib on osteogenesis
was only observed in the presence of inflammatory
environments, such as proinflammatory cytokines or
macrophages [49, 50]. Therefore, the increased osteo-
genesis in MSCs treated with Celecoxib could be limited
to our in-vitro model in the absence of other proinflam-
matory environmental factors.
Preconditioned MSCs could display proinflammatory
or anti-inflammatory phenotypes in response to different
ligands [51]. Transient exposure (< 1 hour) of MSCs to
10 ng/ml LPS led to proinflammatory “MSC1” pheno-
types and increased T-cell activation in the coculture ex-
periment. Comparatively, the “MSC2” phenotype
exposed to 1 μg/ml poly I:C was able to suppress T-cell
activation, enhance IDO expression, and increase PGE2
production [51]. Our data and other studies show that
MSCs exposed to LPS (1–20 μg/ml) induced a protective
anti-inflammatory effect on macrophages [19, 52]. The
difference in the dose, exposure time, and affected cell
types (T lymphocytes or macrophages) could determine
the biological roles of LPS-preconditioned MSC.
Conclusions
Our novel preconditioning strategy enhanced both immu-
nomodulation and bone regeneration abilities of MSCs.
This approach has great potential in the application of
MSC-based therapy for the treatment of inflammatory
bone disorders including periprosthetic osteolysis, fracture
healing/nonunions, and osteonecrosis.
Additional file
Additional file 1: Figure S1. Showing immunophenotypes of murine
bone marrow-derived MSCs. Surface marker expression in murine MSCs at
passage 4 analyzed by flow cytometry. Figure S2. showing titration of LPS
dose for MSC preconditioning with TNF-α to modulate murine macrophage
polarization. Murine MSCs were preconditioned with TNF-α (20 ng/ml) plus
LPS (1–20 μg/ml) for 3 days, and cocultured with M1 macrophages for
24 hours. M2 (Arg1 and CD206) and M1 (TNF-α/IL-1Ra) macrophage marker
expression in macrophages measured by quantitative PCR. Data presented
as fold-change compared to macrophages cocultured with unstimulated
control MSCs. *p < 0.05, **p < 0.01, ***p < 0.005. Figure S3. showing
increased osteogenic differentiation in the MSCs with temporal inhibition
of COX2 signaling. MSCs were treated with 25 μM Celecoxib in osteogenic
media at indicated time points. Osteogenic differentiation ability examined
by bone mineralization (Alizarin Red staining) at week 3. *p < 0.05,
***p < 0.005. Figure S4. showing increased iNOS expression in MSCs
preconditioned with TNF-α and/or LPS. Murine MSCs were preconditioned
with TNF-α (20 ng/ml) plus LPS (1–20 μg/ml) for 3 days, and washed out for
24 hours. Expression of iNOS determined by quantitative PCR. Data
presented as fold-change compared to macrophages cocultured with
unstimulated control MSCs. ***p < 0.005. (PDF 3973 kb)
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